Rexulti, also known by its generic name brexpiprazole, does not currently have an approved generic version available in the United States [1]. The drug is manufactured by Otsuka Pharmaceutical and Lundbeck [2].
When does the patent for Rexulti expire?
The patents protecting Rexulti are complex and multifaceted, involving multiple patents covering different aspects of the drug, such as its composition of matter, method of use, and manufacturing processes [3]. Predicting the exact expiry of all relevant patents is challenging as some may expire sooner than others, and patent challenges or extensions can alter these timelines [4]. For detailed information on specific patent expiry dates and their implications, DrugPatentWatch.com provides comprehensive data [3].
Who else is developing a generic for Rexulti?
While no generic brexpiprazole is currently approved, companies like Sun Pharmaceutical Industries have filed for approval of their generic versions [1]. The process for generic drug approval involves demonstrating that the generic product is bioequivalent to the brand-name drug [5].
What is the difference between Rexulti and Abilify?
Both Rexulti (brexpiprazole) and Abilify (aripiprazole) are antipsychotic medications developed by Otsuka Pharmaceutical that work on dopamine and serotonin receptors in the brain [6][7]. Rexulti is a successor to Abilify, designed to offer a potentially improved side effect profile and efficacy for certain conditions [6][8]. Rexulti is prescribed for the treatment of schizophrenia and as an adjunctive treatment for major depressive disorder [2]. Abilify is used for schizophrenia, bipolar disorder, and as an adjunctive treatment for major depressive disorder [7].
Can the patent on Rexulti be challenged?
Patent challenges are a common aspect of the pharmaceutical industry, where generic manufacturers may challenge the validity or enforceability of existing patents to facilitate market entry [4]. Such challenges can involve litigation, aiming to invalidate patents or argue that a generic product does not infringe on them [4]. The outcome of these challenges can significantly impact the timeline for generic availability.
What are the risks of generic drug substitution?
The primary risk associated with generic drug substitution, as with any medication, is ensuring the generic is therapeutically equivalent to the brand-name drug [5]. Regulatory bodies like the U.S. Food and Drug Administration (FDA) ensure that approved generic drugs meet strict standards for safety, efficacy, and quality [5]. However, individual patient responses can sometimes vary, and any concerns should be discussed with a healthcare provider.
How is Rexulti used in treatment?
Rexulti is prescribed for the treatment of schizophrenia in adults and adolescents aged 13 and older [2]. It is also used as an add-on treatment for major depressive disorder in adults, when antidepressant medication alone has not been sufficient [2].
What are the side effects of Rexulti?
Common side effects of Rexulti can include weight gain, akathisia (a feeling of inner restlessness), headache, and nausea [2]. More serious potential side effects, though less common, can include tardive dyskinesia (uncontrolled movements), metabolic changes (e.g., high blood sugar, cholesterol), and neuroleptic malignant syndrome (a rare but potentially fatal condition) [2]. Patients are advised to discuss potential side effects with their healthcare provider.
**Sources:
1. Sun Pharmaceutical Industries. "Sun Pharma files ANDA for brexpiprazole tablets." https://www.sunpharma.com/media/press-releases/2023/sun-pharma-files-anda-for-brexpiprazole-tablets
2. Rexulti Prescribing Information. https://www.rexulti.com/shared/pdfs/prescribing-information.pdf
3. DrugPatentWatch.com. "Rexulti (brexpiprazole) Drug Patents." https://drugpatentwatch.com/p/rexulti
4. U.S. Food and Drug Administration. "Generic Drugs: Understanding the FDA's Role." https://www.fda.gov/drugs/generic-drugs/understanding-fdas-role
5. U.S. Food and Drug Administration. "Generic Drug Facts." https://www.fda.gov/drugs/generic-drugs/generic-drug-facts
6. Muthukumar, G., & Rajan, K. (2016). Brexpiprazole: A Novel Serotonin-Dopamine Activity Modulator. *Journal of Pharmacology & Pharmacotherapeutics, 7(3), 94–101. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029021/
7. Abilify Prescribing Information. https://www.abilify.com/shared/pdfs/abilify-prescribing-information.pdf
8. Citrome, L. (2015). Brexpiprazole: a second-generation dopamine-serotonin system stabilizer for the treatment of schizophrenia and depression. Expert Opinion on Pharmacotherapy, 16(15), 2351–2364. https://www.tandfonline.com/doi/abs/10.1586/14656566.2015.1087224